Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Chuikyo OKs Application of Huge-Seller Re-Pricing to Opdivo; Payers Loath to Use Ono Sales Outlook for Calculation
October 6, 2016
- 2nd Round of Sakigake Invitations Gets Underway
October 5, 2016
- MOF Pushes for Overhaul of Drug Pricing System, Says It Can’t Address Pricy Meds
October 5, 2016
- Kaketsuken Faces Another Penalty over Encephalitis Vaccine Manufacturing
October 5, 2016
- MHLW, PMDA Set Up “Preparatory Offices” to Plan Future Support System for Startups
October 5, 2016
- MHLW Orders Nagoya Univ. to Probe Corrections Made to Diovan Paper
October 4, 2016
- Bayer Launches Recall of Hemophilia Med Kogenate over Potency Loss
October 4, 2016
- Drug Discovery Support Network to Announce Withdrawn Research Themes; Companies Will Be Able to Use This as “Negative Data”
October 4, 2016
- MHLW Says It Will Compile “Optimal Use Guidelines” for Keytruda Too
October 3, 2016
- Japan’s FY2014 Healthcare Spending Renews Record at 40.8 Trillion Yen
September 30, 2016
- MID-NET Working Group Kicks Off Discussions on Access Fees
September 30, 2016
- MHLW OKs Keytruda, Triple Hypertension Combo Micatrio and Other Drugs
September 29, 2016
- Novartis’ BRAF and MEK Inhibitors Get Orphan Status for NSCLC
September 29, 2016
- Sales of Sovaldi, Harvoni Peaked Out: MHLW
September 29, 2016
- Drug Costs Biggest Driver of Healthcare Spending Surge: Chuikyo JMA Rep
September 29, 2016
- Clinical Research Bill Set to Sail through Extra Diet with Opposition Backing
September 27, 2016
- Japan Inks Memorandums of Cooperation on Pharmacopoeias with US, Europe, China
September 27, 2016
- Lawmaker Group Calls for Launch of Int’l Center for Regenerative Medicine
September 27, 2016
- MHLW to Launch 2nd Round of Sakigake Invitations in Early October
September 26, 2016
- Opdivo under PMDA Review for Myocarditis and Other Risks
September 26, 2016
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…